Reckitt Benckiser Group plc (OTCMKTS:RBGLY – Get Free Report) has received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and three have given a strong buy recommendation to the company.
RBGLY has been the topic of several recent analyst reports. Barclays lowered shares of Reckitt Benckiser Group from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 4th. HSBC upgraded Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Finally, Hsbc Global Res upgraded Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 11th.
View Our Latest Stock Report on RBGLY
Reckitt Benckiser Group Stock Performance
Reckitt Benckiser Group Increases Dividend
The company also recently announced a dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 11th will be paid a dividend of $0.2909 per share. This is a positive change from Reckitt Benckiser Group’s previous dividend of $0.19. The ex-dividend date is Friday, April 11th.
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
See Also
- Five stocks we like better than Reckitt Benckiser Group
- High Flyers: 3 Natural Gas Stocks for March 2022
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Which Wall Street Analysts are the Most Accurate?
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Conference Calls and Individual Investors
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.